Eloxx Posts Smaller-Than-Expected Q3 Loss of 49 Cents a Share
Summary
Eloxx lost 49 cents a share in the September quarter, better than the 58-cent consensus from three analysts, with a net loss of $5.54 million. Revenue was zero, as expected — this is a clinical-stage story, not a sales story. The 8-K filed this morning put cash at $56.3 million, down from $62 million at the end of June, so the burn is real but the runway is still intact. The bigger driver remains the October FDA clearance of the IND for exaluren in nonsense-mutation ADPKD, which lets them start a 60-patient trial; today's beat is a modest positive on top of that. Shares are down 14.1% this quarter despite the trial green light, and the average analyst rating is buy with a median target of $39.00.
At the time of this announcement, ELOX was trading at $13.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.1M. The 52-week trading range was $0.00 to $23.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.